VIASKIN® Peanut (DBV712)
Peanut Allergy (Ages 1-3 years)
Key Facts
About DBV Technologies
DBV Technologies is a pioneer in epicutaneous immunotherapy, developing the VIASKIN® patch as a potential new class of treatment for food allergies and other immunological conditions. Its lead program, VIASKIN® Peanut (DBV712), has completed a Phase 3 trial in toddlers and has an ongoing Phase 3 trial in children aged 4-7, positioning it as a frontrunner in non-invasive allergy desensitization. The company is also advancing programs for cow's milk allergy and exploring broader applications in autoimmune diseases and vaccines, leveraging its unique platform technology.
View full company profileAbout DBV Technologies
DBV Technologies is a pioneer in epicutaneous immunotherapy, developing the VIASKIN® patch as a potential new class of treatment for food allergies and other immunological conditions. Its lead program, VIASKIN® Peanut (DBV712), has completed a Phase 3 trial in toddlers and has an ongoing Phase 3 trial in children aged 4-7, positioning it as a frontrunner in non-invasive allergy desensitization. The company is also advancing programs for cow's milk allergy and exploring broader applications in autoimmune diseases and vaccines, leveraging its unique platform technology.
View full company profileAbout DBV Technologies
DBV Technologies is a pioneer in epicutaneous immunotherapy, developing the VIASKIN® patch as a potential new class of treatment for food allergies and other immunological conditions. Its lead program, VIASKIN® Peanut (DBV712), has completed a Phase 3 trial in toddlers and has an ongoing Phase 3 trial in children aged 4-7, positioning it as a frontrunner in non-invasive allergy desensitization. The company is also advancing programs for cow's milk allergy and exploring broader applications in autoimmune diseases and vaccines, leveraging its unique platform technology.
View full company profile